Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age
David Hosking(Nottingham City Hospital), A.J.P. Yates(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael R. McClung(Bone Health and Osteoporosis Foundation), Pernille Ravn(Center for Clinical & Basic Research), Desmond Thompson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marianne Daley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard D. Wasnich(Bone Health and Osteoporosis Foundation), Philip D. Ross(Bone Health and Osteoporosis Foundation), Claus Christiansen(Université Claude Bernard Lyon 1), Clair E.D. Chilvers(University of Nottingham), Ana Balske(Providence Center)
Cited by 487
Related Papers
The diagnosis of osteoporosis
|Journal of Bone and Mineral Research|1994|3.9k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k